Time-to-progression (TTP) was defined as the time interval from study enrollment to the date of first documented disease progression.
The cohort members were followed up for cancer incidence in the population-based Danish Cancer Registry (Storm et al. 1997) from the time of enrollment until the date of first cancer diagnosis, emigration, death, or 1 August 2003, whichever came first.
Subjects contributed person-time at risk from year of enrollment (1993 1997) through 31 December 2007, date of first cancer diagnosis or date moved out of the state, whichever was earlier.
Baastrup et al. (2008) reported on 56,378 Danish men and women, 50 64 years of age at enrollment between 1993 and 1997, who were followed until date of first cancer diagnosis, emigration, death, or 1 August 2003.
Date of first death in the family.
Patients with all of the following data were included in the current analysis of enrollment characteristics: 1) date of birth, gender, Registry enrollment date; 2) knowledge of treatment with eculizumab or no previous eculizumab treatment; and 3) for eculizumab-treated patients, date of first eculizumab dose.
Date of second submission: 3.09.2014.
The index date for control subjects was the first day (for those enrolled prior to 2000) or the first date of enrollment to the National Health Insurance in 2000.
For each participant, we calculated person time from date of enrollment until the first event (non-fatal AMI or fatal CHD), date of emigration (n = 693), date of death or censoring date (1 January 2006), whichever occurred first.
